Gainers
- ShiftPixy, Inc. (NASDAQ:PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
- Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 51% to settle at $27.03 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets.
- Rubius Therapeutics, Inc. (NASDAQ:RUBY) climbed 48.6% to close at $1.29 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share.
- Benitec Biopharma Inc. (NASDAQ:BNTC) shares gained 33% to close at $0.7880. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.
- Marker Therapeutics, Inc. (NASDAQ:MRKR) rose 31.5% to close at $0.3999 after the company's Phase 2 study of multi-tumor-associated antigen-specific T cell therapy for relapsed/refractory AML appeared on the FDA's Orphan Products Grants Program site.
- Palatin Technologies, Inc. (NYSE:PTN) gained 26.2% to close at $6.31 after the company announced the initiation of patient recruitment for its Phase 2 study evaluating oral PL8177 in ulcerative colitis.
- LifeStance Health Group, Inc. (NASDAQ:LFST) jumped 25.8% to close at $9.57. LifeStance Health named Ken Burdick as CEO and Chairman.
- T Stamp Inc. (NASDAQ:IDAI) gained 25% to settle at $1.85.
- Asana, Inc. (NYSE:ASAN) shares gained 24.8% to close at $23.76 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock.
- Relay Therapeutics, Inc. (NASDAQ:RLAY) gained 23.8% to close at $31.37. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial.
- Revance Therapeutics, Inc. (NASDAQ:RVNC) gained 21.6% to close at $25.30 after the company announced FDA approval of DAXXIFY for injection for temporary improvement of moderate to severe frown lines.
- SPAR Group, Inc. (NASDAQ:SGRP) rose 21.3% to close at $1.54 after the company's board of directors initiated a process to evaluate potential strategic alternatives including a sale, merger or other strategic transaction.
- Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 20.4% to settle at $1.30.
- Eve Holding, Inc. (NYSE:EVEX) jumped 20% to close at $7.39. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) climbed 18.9% to settle at $708.85 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
- Eyenovia, Inc. (NASDAQ:EYEN) gained 18.6% to close at $2.48.
- VistaGen Therapeutics, Inc. (NASDAQ:VTGN) jumped 18.4% to close at $0.1953 after the company announced the completion of an interim analysis of its PALISADE-2 Phase 3 clinical trial of PH94B.
- IVERIC bio, Inc. (NASDAQ:ISEE) gained 18.3% to settle at $17.68 after Stifel maintained a Buy rating on the stock and raised its price target from $28 to $35.
- First High-School Education Group Co., Ltd. (NYSE:FHS) gained 17% to close at $0.75.
- Lyft, Inc. (NASDAQ:LYFT) gained 16.9% to close at $17.17 amid vague rumors from a questionable source mentioning the company.
- NantHealth, Inc. (NASDAQ:NH) jumped 16.4% to close at $0.4788.
- Venus Concept Inc. (NASDAQ:VERO) gained 15.8% to close at $0.7473.
- Annovis Bio, Inc. (NYSE:ANVS) climbed 15.7% to settle at $12.19 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $40 price target.
- Phreesia, Inc. (NYSE:PHR) rose 15.6% to close at $27.64 after the company reported better-than-expected Q2 sales results and raised the low-end of its FY23 sales guidance.
- Tandem Diabetes Care, Inc. (NASDAQ:TNDM) jumped 15.3% to close at $52.61.
- AeroVironment, Inc. (NASDAQ:AVAV) gained 14.9% to close at $101.87 after reporting upbeat quarterly sales.
- Immunocore Holdings plc (NASDAQ:IMCR) rose 14.9% to settle at $57.44 after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced an $82 price target.
- Terns Pharmaceuticals, Inc. (NASDAQ:TERN) gained 14.7% to close at $4.36.
- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) rose 14.4% to close at $23.86. Rhythm Pharmaceuticals announced new employment inducement grants. Goldman Sachs maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $28 to $31.
- Cazoo Group Ltd (NYSE:CZOO) gained 13.5% to close at $0.6921. The company announced it will wind down operations in mainland Europe to focus on core UK market.
- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) jumped 11.3% to close at $49.93.
- Rivian Automotive, Inc. (NASDAQ:RIVN) gained 10.9% to close at $36.88 after the company and Mercedes-Benz Vans signed a Memorandum of Understanding for a strategic partnership.
- John Wiley & Sons, Inc. (NYSE:WLY) gained 10.8% to settle at $46.08. CJS Securities upgraded John Wiley & Sons from Market Perform to Market Outperform.
- Allego N.V. (NYSE:ALLG) rose 9.6% to close at $4.33. Allego recently announced first half financial results and 2022 revenue expectations.
- Heliogen, Inc. (NYSE:HLGN) rose 9.5% to close at $2.42.
- Albireo Pharma, Inc. (NASDAQ:ALBO) surged 9.4% to close at $18.23. Guggenheim initiated coverage on Albireo Pharma with a Buy rating and announced a price target of $55.
- Snap Inc. (NYSE:SNAP) rose 9.3% to close at $12.53 on continued strength after a recent internal memo obtained by The Verge suggested the company is aiming to reach $6 billion in revenue and 450 million users by next year.
- Intapp, Inc. (NASDAQ:INTA) rose 8.5% to close at $15.95 after the company reported better-than-expected Q4 results and issued guidance above estimates.
- GameStop Corp. (NYSE:GME) rose 7.5% to close at $25.83 after the company reported better-than-expected earnings for its second quarter and also announced a partnership with cryptocurrency exchange FTX to bring more customers to the digital asset space.
- Zillow Group, Inc. (NASDAQ:ZG) gained 6.3% to close at $37.58 after Jefferies maintained a Buy rating on the stock and raised its price target from $48 to $50.
